Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
News|Slideshows|May 28, 2024
ICYMI: Drug Topics May 2024 Issue
Author(s)Lauren Massaro
Don’t miss out on the latest pharmacy insights in the Drug Topics May issue.
Advertisement
The May 2024 issue of Drug Topics is packed with the latest news and insights in pharmacy. Catch up on stories regarding the rise in e-prescription fraud, the dual treatment of type 1 diabetes and obesity, how pharmacy practices in Germany compare to those in the US, and more.
To read these stories and more,
Don’t get left behind: Sign up today for our
Advertisement
Related to this article
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.
As pharmacists vocalize their willingness to fill in health care gaps, the integration of public health and emerging pharmacy professionals could be profound.
The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.
A persistence of pneumococcal meningitis among adults transformed the disease into a public health concern pharmacists fight on a population-wide scale.
An analysis found all-cause pneumonia Black, lower-income, and medically at-risk children still face substantially higher rates of hospitalization.
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
3
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
4
Expert Discusses Flu and COVID-19 Vaccine Guidance
5